Amgen AMGN announced that it has acquired U.K.-based private biotech company, Dark Blue Therapeutics, for approximately $840 million. The acquisition will strengthen Amgen’s oncology pipeline by ...

The deal brings Dark Blue's preclinical oncology products, including an MLLT1/3-targeted agent for leukemias, into Amgen's portfolio.

Amgen acquires Dark Blue Therapeutics for up to $840 million, adding early-stage leukemia drug research and strengthening its oncology discovery pipeline.

Amgen Inc. has acquired cancer drug developer Dark Blue Therapeutics Ltd. in a deal worth as much as $840 million, expanding its portfolio of oncology treatments.